Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 12/20 | 0.42 |
| ▸ | NPY1R | P25929 | 8/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.42 |
| ▸ | NPY2R | P49146 | 5/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30685283 | 0.93 | NPY4R (0.45) | GNPATNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30792489 | 0.92 | GNPAT (0.43) | GNPATNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31571454 | 0.92 | NPY4R (0.41) | GNPATNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL9819642 | 0.90 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL9819648 | 0.90 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29697049 | 0.90 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30140870 | 0.90 | NPY4R (0.47) | GNPATNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29772950 | 0.90 | FOLH1 (0.45) | GNPATNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30683549 | 0.90 | FOLH1 (0.45) | GNPATNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30685304 | 0.88 | NPY4R (0.40) | GNPATNPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028389-A1 | FUSION PROTEIN INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-01-29 | — | — | US | claimed |
| EP-4561611-A2 | FUSION PROTEIN INHIBITORS OF KLK5 | Biocryst Pharmaceuticals, Inc. (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024020083-A2 | FUSION PROTEIN INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-01-25 | — | — | WO | claimed |
| US-20260028389-A1 | FUSION PROTEIN INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-01-29 | — | — | US | disclosed |
| EP-4561611-A2 | FUSION PROTEIN INHIBITORS OF KLK5 | Biocryst Pharmaceuticals, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4370150-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | Intervet International B.V. (NL) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024020083-A2 | FUSION PROTEIN INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-116535490-B | Polypeptide ADSCP8 for reducing collagen content of scar dermis fibroblast and application thereof | 南京市妇幼保健院 | 2023-12-01 | — | — | CN | disclosed |
| CN-116535490-A | Polypeptide ADSCP8 for reducing collagen content of scar dermis fibroblast and application thereof | 南京市妇幼保健院 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023285489-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | INTERVET INTERNATIONAL B.V. (NL) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028389-A1 | FUSION PROTEIN INHIBITORS OF KLK5 | KLK1, KLK5, KLK2 | GNPAT 4880/4885NPY4R 785/4885NPY1R 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.